J&J buys an early-stage gene therapy for the eye — the only known program for an under-the-radar biotech
Just weeks after MeiraGTx touted their latest update on data emerging from their gene therapy alliance with J&J on inherited retinal diseases, the pharma giant is back with an acquisition tailored to beef up their R&D efforts in the field.
This deal is focused on HMR59, an early-stage gene therapy at a small biotech called Hemera Biosciences. They’re keeping the terms under wraps for now, but J&J is grabbing a once-and-done gene therapy that is designed to protect levels of CD59, a key protein that guards the retina.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
